Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: Glecaprevir/pibrentasvir (G/P) is a combination of direct-acting antiviral agents that is an approved treatment for chronic infections by all six hepatitis C virus (HCV) genotypes. However, there are limited data on the effect of G/P in Korean patients in actual real-world settings. We evaluated the real-life effectiveness and safety of G/P at a single institution in Korea. Methods: This retrospective, observational, cohort study used sustained virologic response at 12 weeks after treatment completion (SVR12) as the primary effectiveness endpoint. Safety and tolerability were also determined. Results: We examined 267 individuals who received G/P for chronic HCV infections. There were 148 females (55.4%), and the overall median age was 63.0 years (range, 25 to 87 years). Eightythree patients (31.1%) had HCV genotype-1 and 182 (68.2%) had HCV-2. A total of 212 patients (79.4%) were HCV treatment-naïve, 200 (74.9%) received the 8-week treatment, 13 (4.9%) had received prior treatment for hepatocellular carcinoma, 37 (13.7%) had chronic kidney disease stage 3 or higher, and 10 (3.7%) were receiving dialysis. Intention to treat (ITT) analysis indicated that 256 (95.9%) achieved SVR12. A modified ITT analysis indicated that SVR12 was 97.7% (256/262). Six patients failed therapy because of posttreatment relapse. SVR12 was significantly lower in those who received prior sofosbuvir treatment (p=0.002) and those with detectable HCV RNA at week 4 (p=0.027). Seventy patients (26.2%) experienced one or more adverse events, and most of them were mild. Conclusions: These real-life data indicated that G/P treatment was highly effective and well tolerated, regardless of viral genotype or patient comorbidities.
Abstract
Background/Aims: Glecaprevir/pibrentasvir (G/P) is a combination of direct-acting antiviral agents that is an approved treatment for chronic infections by all six hepatitis C virus (HCV) genotypes. However, there are limited data on the effect of G/P in Korean patients in actual real-world settings. We evaluated the real-life effectiveness and safety of G/P at a single institution in Korea. Methods: This retrospective, observational, cohort study used sustained virologic response at 12 weeks after treatment completion (SVR12) as the primary effectiveness endpoint. Safety and tolerability were also determined. Results: We examined 267 individuals who received G/P for chronic HCV infections. There were 148 females (55.4%), and the overall median age was 63.0 years (range, 25 to 87 years). Eightythree patients (31.1%) had HCV genotype-1 and 182 (68.2%) had HCV-2. A total of 212 patients (79.4%) were HCV treatment-naïve, 200 (74.9%) received the 8-week treatment, 13 (4.9%) had received prior treatment for hepatocellular carcinoma, 37 (13.7%) had chronic kidney disease stage 3 or higher, and 10 (3.7%) were receiving dialysis. Intention to treat (ITT) analysis indicated that 256 (95.9%) achieved SVR12. A modified ITT analysis indicated that SVR12 was 97.7% (256/262). Six patients failed therapy because of posttreatment relapse. SVR12 was significantly lower in those who received prior sofosbuvir treatment (p=0.002) and those with detectable HCV RNA at week 4 (p=0.027). Seventy patients (26.2%) experienced one or more adverse events, and most of them were mild. Conclusions: These real-life data indicated that G/P treatment was highly effective and well tolerated, regardless of viral genotype or patient comorbidities.
참고문헌 (42)
- Li G, "Current therapy for chronic hepatitis C : the role of direct-acting antivirals", Antiviral Res, 142, pp.83~122 (2017)
- European Association for the Study of the Liver, "EASL recommendations on treatment of hepatitis C 2018", J Hepatol, 69, pp.461~511 (2018)
- AASLD-IDSA HCV Guidance Panel, "Hepatitis C guidance 2018 update : AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection", Clin Infect Dis, 67, pp.1477~1492 (2018)
- "EPCLUSA (sofosbuvir/velpatasvir)summary of product characteristics" (2020)[URL]
- "VOSEVI (sofosbuvir/velpatasvir/voxilaprevir) summary of product characteristics" (2019)[URL]
- "MAVIRET (glecaprevir/pibrentasvir) summary of product characteristics" (2019)[URL]
- "Chronic Hepatitis Treatment/National Health Insurance Service Guide" (2019)[URL]
- Gane E, "High efficacy of ABT-493and ABT-530 treatment in patients with HCV genotype 1or 3 infection and compensated cirrhosis", Gastroenterology, 151, pp.651~659 (2016)
- Kwo PY, "Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis", J Hepatol, 67, pp.263~271 (2017)
- Muir AJ, "High SVR rates with ABT-493+ ABT-530 co-administered for 8 weeks in noncirrhotic patients with HCV genotype 3 infection", J Hepatol, 64(Suppl 2), pp.S186~ (2016)
- Zeuzem S, "Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection", N Engl J Med, 378, pp.354~369 (2018)
- Wyles D, "Glecaprevir", pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and, Hepatology, pp.2018, 67[DOI]
- Asselah T, "Efficacy of glecaprevir", pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis, 2018, pp.16, 417~426
- Forns X, "Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis(EXPEDITION-1) : a single-arm, open-label, multicentre phase 3 trial", Lancet Infect Dis, 17, pp.1062~1068 (2017)
- Puoti M, "High SVR12 with 8-week and 12-week glecaprevir", pibrentasvir therapy : an integrated analysis of HCV genotype 1-6 patients without cirrhosis, 2018, pp.69, 293~300
- Young Min Kim, "Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study", Clinical and Molecular Hepatology, 24(3), pp.311~318 (2018), 대한간학회
- Jong Eun Yeon, "Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?", Clinical and Molecular Hepatology, 24(3), pp.294~296 (2018), 대한간학회
- 한성용, "The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2", The Korean Journal of Internal Medicine, 36(3), pp.544~556 (2021), 대한내과학회[DOI]
- D’Ambrosio R, "Real-world effectiveness and safety of glecaprevir", pibrentasvir in 723 patients with chronic hepatitis C, 2019, pp.70, 379~387
- Berg T, "Real-world effectiveness and safety of glecaprevir", pibrentasvir for the treatment of chronic hepatitis C infection : data from the German Hepatitis C-Registry, 2019, pp.49, 1052~1059
- Hsu SJ, "Real-world effectiveness and safety of glecaprevir", pibrentasvir in Asian patients with chronic hepatitis C, 2019, pp.118, 1187~1192
- The Korean Association for the Study of the Liver, "KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications", Clinical and Molecular Hepatology, 24(3), pp.169~229 (2018), 대한간학회
- European Association for Study of Liver, "EASL-ALEH Clinical Practice Guidelines : non-invasive tests for evaluation of liver disease severity and prognosis", J Hepatol, 63, pp.237~264 (2015)
- "Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group", Hepatology, 20(1Pt 1), pp.15~20 (1994)
- Levey AS, "Definition and classification of chronic kidney disease : a position statement from Kidney Disease : Improving Global Outcomes(KDIGO)", Kidney Int, 67, pp.2089~2100 (2005)
- Kim DY, "A nationwide seroepidemiology of hepatitis C virus infection in South Korea", Liver Int, 33, pp.586~594 (2013)
- Gower E, "Global epidemiology and genotype distribution of the hepatitis C virus infection", J Hepatol, 61(1 Suppl), pp.S45~S57 (2014)
- Kim BK, "Current status of and strategies for hepatitis C control in South Korea", Clin Mol Hepatol, 23, pp.212~218 (2017)
- Hajarizadeh B, "Epidemiology and natural history of HCV infection", Nat Rev Gastroenterol Hepatol, 10, pp.553~562 (2013)
- Liu CH, "Glecaprevir", pibrentasvir for patients with chronic hepatitis C virus infection : real-world effectiveness and safety in Taiwan, 2020, pp.40, 758~768
- Ogawa E, "Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection : results from a multicenter, realworld cohort study", Hepatol Res, 49, pp.617~626 (2019)
- Tamori A, "Intention-to-treat assessment of glecaprevir + pibrentasvir combination therapy for patients with chronic hepatitis C in the real world", Hepatol Res, 49, pp.1365~1373 (2019)
- Brown RS Jr, "Glecaprevir", pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis : the EXPEDITION-8 trial, 2020, pp.72, 441~449
- Pol S, "Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection : from the clinical trials to real life", Hepat Med, 8, pp.21~26 (2016)
- Svarovskaia ES, "Infrequent development of resistance in genotype 1-6 hepatitis C virusinfected subjects treated with sofosbuvir in phase 2 and 3clinical trials", Clin Infect Dis, 59, pp.1666~1674 (2014)
- Hedskog C, "Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy", J Viral Hepat, 22, pp.871~881 (2015)
- Krishnan P, "Integrated resistance analysis of CERTAIN-1 and CERTAIN-2 studies in hepatitis C virus-infected patients receiving glecaprevir and pibrentasvir in Japan", Antimicrob Agents Chemother, 62, pp.e02217~17 (2018)
- Wang C, "Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6 : implications for cross-genotype activity", Antimicrob Agents Chemother, 58, pp.5155~5163 (2014)
- Cheng G, "In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir", Antimicrob Agents Chemother, 60, pp.1847~1853 (2016)
- Schnell G, "Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir", ritonavir, 2018, pp.90, 109~119
- Ng TI, "In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS3", 4A protease inhibitor glecaprevir, 2017, pp.62, e01620~17
- Ng TI, "In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir", Antimicrob Agents Chemother, 61, pp.e02558~16 (2017)